Established product line and quality control system

  • OrigiMed was founded
  • Financing was kicked off
  • Involved in the publication of the first 'CAGC Consensus on the Clinical Application of Next -generation Sequencing'  in China
  • Launched YuanSu (元溯), the very first broad gene panel on the market

Precision medicine and patient management at all stages

  • Started series A financing
  • The only bioinformatic analysis team recognized by the Chinese Research Center of the U.S. Cancer MoonshotSM
  • Rewarded as a National New High-tech Enterprise
  • Invented OriLongindel and Orifusion algorithms that were the most advanced in the industry
  • Joined the Chinese Society of Clinical Oncology (CSCO)
  • Launched the first commercialized PD-L1 IHC test in China
  • Invented YuanSu S (元溯S), the first broad gene panel combined both DNA and RNA sequencing
  • Invented QiYuan ctDNA (启源) with broad gene panel
  • Launched Dr Groundhog APP, the first online oncological patient management platform

Big data platform

  • Series B financing
  • Joined the National Digital Health Center (North China) in Jinan
  • Received CAP accreditation
  • Received CLIA certificate
  • Launched ZhiXun WES+, the first comprehensive WGS with broad gene panel in China
  • Invented YuanSu IOTM, based on immune checkpoints with broad gene panel
  • Established the first oncological Internet Hospital focusing on precision medicine in China
  • Established ICRN - OrigiMed precision medicine platform for hepatobiliary cancer
  • Established CSCO - ECCO -OrigiMed big data platform for genomic information
  • Established Molecular Tumor Board, international consultation

One-stop solutions for pharmaceutical companies

  • Collaboration with Bayer in developing the first NGS-based CDx kit
  • Publication of biomarker discovery for new drug R&D in the Journal of Clinical Oncology
  • Received the Medical Device Business License of China
  • The first Chinese publication of NGS validation in The Oncologist
  • Publication of proteogenomic research on hepatocellular carcinoma in Cell
  • Partnership with CTONG - OrigiMed innovative platform for clinical trial sharing
  • Established the online international molecular pathological platform
  • Participated in the biggest Real World Study on soft tissue sarcoma and bone cancer in China
  • The largest international demonstration center of precision medicine on hepatobiliary cancer

Established OrigiMed Smart Data Center

  • Formed OrigiMed Cancer Precision Medicine Experts Group in Hainan
  • Qualified to conduct COVID-19 nucleic acid testing as one of the first institutes in Shanghai
  • Published the article of the first Chinese assay with broad gene panel comparing with the one approved by FDA on 《JCO Precision Oncology》
  • Involved in the publication of the first Experts Consensus on Clinical Application of Molecular Hepatobiliary Cancer Diagnosis in China
  • Signed the agreement on the strategic collaboration with Takeda China
  • Completed the enrolment for the first NGS-based CDx clinical trial
  • Co-developed multiple NGS-based CDx kits
  • Invented BenXi, the broad panel test for hematological malignancies
  • Participated in the project of molecular pathology in soft tissue sarcoma and bone cancer in China
  • Participated in the Real World Study on breast cancer in young females